Related Experiment Video
Updated: Jun 28, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab
Shana Marmon1, Bruce E Strober2
1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA.
Although effective in the treatment of immunodysregulatory diseases such as psoriasis, targeted immunosuppressive agents may confer risks of both enhanced susceptibility to infection and decreased responsiveness to vaccination. In a recent study, Krueger et al. (this issue) investigated these issues by testing the immune response to both a model antigen and a therapeutic vaccination in psoriasis patients during and after treatment with an LFA-1 inhibitor, efalizumab.
Although effective in the treatment of immunodysregulatory diseases such as psoriasis, targeted immunosuppressive agents may confer risks of both enhanced susceptibility to infection and decreased responsiveness to vaccination. In a recent study, Krueger et al. (this issue) investigated these issues by testing the immune response to both a model antigen and a therapeutic vaccination in psoriasis patients during and after treatment with an LFA-1 inhibitor, efalizumab.
Related Concept Videos
Tumor Immunotherapy
Vaccinations
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Vaccines
Cross-reactivity
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
